Background
The central nervous system (CNS) can activate innate immune responses by sensing pathogens or tissue damages [
1]. Upon acute traumatic spinal cord injury, the resident immune and glial cells are rapidly motivated to release various cytokines and chemokines, which further induce leukocyte infiltration to the injury sites [
2,
3]. Astrocytes are the most abundant glial cell contributing to the functional homeostasis of the healthy CNS. They can also receive and integrate information from synapses, other glial cells, and the blood vessels and as a consequence generate complex outputs that control the neural circuitry and coordinate it with the local microcirculation [
4]. Astrocytes have been shown to participate in local inflammatory responses [
5‐
8]. In the context of inflammatory or otherwise pathological conditions, the activated astrocytes proliferate and produce a wide variety of cytokines and chemokines, including CCL2 (monocyte chemotactic protein-1), CCL5 (RANTES), and CXCL8 (IL-8), which are associated with the recruitment of immune cells of alternative activation status [
5,
9]. These recruited microglia/macrophages play either a pro-inflammatory (M1) or anti-inflammatory (M2) role as seen in a spinal cord injury model or neuroinflammatory diseases like multiple sclerosis (MS) [
10]. Chemokine (C-C motif) ligand 5 (CCL5) may serve to amplify inflammatory responses by facilitating the recruitment of inflammatory cells into autoimmune lesions [
6,
11,
12]. As such, astrocyte-released cytokines and chemokines which contribute to inflammatory responses will inevitably exacerbate the neuropathological changes following CNS injury.
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine produced by a variety of cells and tissues, including monocytes, the anterior pituitary gland, T-lymphocytes, hepatocytes, and keratinocytes [
13,
14]. MIF has been found to be constitutively or inducibly expressed in astrocytes, neurons, microglia, ependymal cells, and epithelial cells of the choroid plexus in the CNS [
14‐
17]. Besides its roles of inducing neuronal death and activating inflammatory episodes in microglia, MIF is capable of promoting proliferation and inflammatory cytokine production of astrocytes [
16,
18]. Deletion of MIF has been shown to promote functional recovery after compression-induced spinal cord injury [
17], suggesting that MIF plays key roles in the neuropathogenesis of injured spinal cord. Astrocytes are the main sources of chemokines involved in recruitment of inflammatory cells; whether MIF is able to induce the release of chemokines from the cells remains unclear.
Astrocytes are endowed with the ability to secrete cytokines through expressing an array of receptors involved in innate immunity, such as Toll-like receptors and nucleotide-binding oligomerization domains [
19,
20]. Also, the cells express CD74 surface receptor which can interact with MIF to elicit inflammatory responses after spinal cord injury (SCI) [
18]. As MIF/CD74 axis has been found to activate intracellular MAPKs of astrocytes, an intermediate signaling essential for regulation of CCL5 and other chemokines [
21,
22], MIF/CD74 axis is therefore postulated to mediate the production of CCL5 in astrocytes, which has been identified to promote inflammatory cell recruitment. In the present study, we analyzed the correlations between expression of MIF and CCL5 in the injured spinal cord of rat. We further investigated MIF-induced production of CCL5 in the astrocytes, as well as the underlying molecular mechanism. Our results have revealed that MIF affects pathological changes of the injured spinal cord through not only activation of astrocyte inflammatory responses, but also promoting release of chemokines.
Methods
Animals
Adult male Sprague–Dawley (SD) rats, weighing 180–220 g, were provided by the Center of Experimental Animals, Nantong University. All animal care, breeding, and testing procedures were approved according to the Animal Care and Use Committee of Nantong University and the Jiangsu Province Animal Care Ethics Committee. All animals were housed in individual cages in a temperature and light/dark cycle controlled environment with free access to food and water.
Establishment of the contusion SCI rat model
The number of animals subjected to surgical treatment was calculated by six per experimental group in triplicate. The contusion SCI rat model was prepared as the previous description [
23]. Briefly, rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate (3 mg/kg). The fur was shaved from the surgical site and the skin was disinfected with chlorhexidine. A 15-mm midline skin incision was made to expose the vertebral column. After the spinal thoracic region was exposed by separation of the dorsal muscles to the side, the spinous processes of T8–T10 vertebrae were exposed. A laminectomy was performed at vertebral level T9, exposing the dorsal cord surface with the dura remaining intact. The exposed spinal cord segment (about 3 mm in length) received a 150-kilodyne spinal contusion injury using the IH-0400 Impactor (Precision Systems and Instrumentation) injury device. The impact rod was removed immediately, and the wound was irrigated. Muscles and incisions were sutured using silk threads. Postoperative care included butorphanol administration twice a day for a 5-day period, as well as vitamins, saline, and enrofloxacin twice a day for a 7-day period. Manual expression of the bladders was performed twice a day until animals recovered spontaneous voiding.
Cell culture
Astrocytes were prepared from the spinal cord of newborn Sprague–Dawley rats, 1–2 days after birth, and the astrocytes were isolated and cultured according to previously described methods [
24]. Briefly, the cells were enzymatically dissociated using 0.25% trypsin (Gibco-BRL) for 6 min at 37 °C, and the suspension was then centrifuged at 1200 rpm for 5 min and cultured in 1:1 Dulbecco’s modified Eagle’s medium to Ham’s F-12 medium supplemented with 10% fetal bovine serum (FBS), 0.224% NaHCO
3, and 1% penicillin/streptomycin in the presence of 5% CO
2. A monolayer of astrocytes was obtained 12–14 days after the plating. Non-astrocytes were detached from the flasks by shaking and were removed by changing the medium. Third or fourth passage cells were rendered quiescent through incubation in the medium containing 0.5% FBS for 4 days prior to the experiments. Astrocyte phenotype was confirmed by cells exhibiting a characteristic morphology and positive staining for the astrocytic marker glial fibrillary acid protein (GFAP).
Western blot
Protein was extracted from cells with a buffer containing 1% SDS, 100 mM Tris-HCl, 1 mM PMSF, and 0.1 mM β-mercaptoethanol, following treatment with 0.5 μg/ml rat recombinant MIF (ProSpec) for 15 min, 30 min, and 60 min, respectively. Alternatively, protein was extracted from 1-cm spinal segments of the injured site at 0 day, 1 day, 4 days, and 1 week following contusion (n = 8 in each time point). Protein concentration of each specimen was detected by the Bradford method to maintain the same loads. Protein extracts were heat-denatured at 95 °C for 5 min, electrophoretically separated on 10% SDS-PAGE, and transferred to PVDF membranes. The membranes were subjected to the reaction with a 1:1000 dilution of primary antibodies in TBS buffer at 4 °C overnight, followed by a reaction with the secondary antibody conjugated with goat anti-rabbit or goat anti-mouse HRP dilution 1:1000 (Santa Cruz) at room temperature for 2 h. After the membrane was washed, the HRP activity was detected using an ECL kit. The image was scanned with a GS800 Densitometer Scanner (Bio-Rad), and the data were analyzed using PDQuest 7.2.0 software (Bio-Rad). β-actin (1:5000) was used as an internal control. The antibodies used in Western blot are as follows: MIF (Abcam); p65NFκB (Cell Signaling Technology, CST), p-ERK1/2, and ERK1/2 (CST); and CD74 (Biorbyt) and β-actin (Proteintech).
ELISA
Primary astrocytes were treated with 0–2.5 μg/ml rat recombinant MIF for 24 h, or tissue samples of spinal segments were prepared as mentioned (n = 6 in each time point). Cell supernatants were harvested, and cells were lysed in the buffer containing 1% SDS, 100 mM Tris-HCl, 1 mM PMSF, and 0.1 mM β-mercaptoethanol. The lysates were centrifuged at 12,000g for 15 min. Levels of CCL5 were assessed using the appropriate ELISA kits (BD Biosciences, R&D Systems) according to the manufacturer’s directions. Plates were read using a 96-well plate reader (Biotek Synergy2) at a 450-nm wavelength.
Tissue immunohistochemistry
The vertebra segments were harvested from six experimental models of each time point, post-fixed, and sectioned. Sections were allowed to incubate with monoclonal MIF antibody (1:200 dilution), rabbit anti-IBA-1 antibody (1:400 dilution, Wako), polyclonal rabbit anti-CCL5 antibody (1:200 dilution, novusbio), or monoclonal mouse anti-human GFAP antibody (1:400 dilution, Sigma) at 4 °C for 36 h. The sections were further reacted with the FITC-labeled secondary antibody goat anti-mouse IgG (1:400 dilution, Gibco) or the TRITC-labeled secondary antibody donkey anti-rabbit IgG (1:400 dilution, Gibco) at 4 °C overnight, followed by observation under a confocal laser scanning microscope (Leica, Heidelberg, Germany).
Immunoprecipitation
The primary astrocytes were washed twice with cold phosphate-buffered saline and then extracted with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and Roche Applied Science’s complete protease inhibitors). Whole-cell extracts were centrifuged at 14,000 rpm for 20 min to remove the debris. The proteins in the supernatant were measured using a Protein Assay Kit II (Bio-Rad). For immunoprecipitation analysis, 500 μg of total cell lysates was precleared with protein A plus G-Sepharose before incubation with specific antibodies, followed by addition of protein A plus G-Sepharose. The precipitated proteins were resolved in 2× SDS-PAGE sample buffer and separated by electrophoresis on 10–12% SDS-PAGE. After being transferred onto a polyvinylidene difluoride membrane (Millipore Corp.), they were incubated with anti-MIF or anti-CD74 antibody and further with horseradish peroxidase-conjugated secondary antibody (Santa Cruz).
Transwell migration assay
Migration of RAW264.7 cells were measured using 6.5-mm transwell chambers with 8-μm pores (Costar, Cambridge, MA) as described previously [
25]. A total of 100 μl of RAW264.7 cells (2 × 10
5 cells/ml) was transferred into the top chamber of the transwells and allowed to migrate at 37 °C in 5% CO
2. Meanwhile, 600 μl of astrocytes (1 × 10
5 cells/ml) was seeded into the lower chambers. After migration for 48 h, the upper surface of each membrane was cleaned with a cotton swab. Cells attached to the bottom surface of each membrane were stained with 0.1% crystal violet, imaged, and counted using a DMR inverted microscope (Leica Microsystems, Bensheim, Germany). Assays were performed in triplicate for three times. To determine the effect of CCL5 on astrocyte-stimulated RAW264.7 migration, astrocytes were stimulated with 0.5 μg/ml recombinant MIF following CCL5 siRNA interference for 24 h prior to a transwell assay. For M2 macrophage transition, RAW264.7 cells were treated with or without 20 ng/ml rat recombinant IL-13 for 2 days.
Sequencing of mRNA
Total RNA of astrocytes following treatment with CD74-siRNA [
18] or scramble for 48 h, and then with 2.0 μg/ml recombinant MIF for 12 h and 24 h, respectively, was extracted using the mirVana miRNA Isolation Kit (Ambion, Austin, TX) according to the manufacturer’s instructions. They were then selected by RNA Purification Beads (Illumina, San Diego, CA) and undergone library construction and RNA-seq analysis. The library was constructed by using the Illumina TruSeq RNA sample Prep Kit v2 and sequenced by the Illumina HiSeq-2000 for 50 cycles. High-quality reads that passed the Illumina quality filters were kept for the sequence analysis.
Differentially expressed mRNA was designated in a criterion of greater than twofold or less than twofold change in comparison with control. Function of genes was annotated by Blastx against the NCBI database or the AGRIS database (
https://agris-knowledgebase.org/) with
E value threshold of 10
−5. Gene ontology (GO) classification was obtained by WEGO (
http://wego.genomics.org.cn/) via GO id annotated by Perl and R program. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were assigned to the sequences using KEGG Automatic Annotation Server (KAAS) online. For all heatmaps, genes were clustered by Jensen-Shannon divergence.
A reconstructed gene network was created using the Ingenuity Pathway Analysis (IPA) Software on the basis of differentially expressed genes (fold change < 0.5 for downregulated genes at 12 h and 24 h following CD74 knockdown) to investigate their regulatory pathways and cellular functions [
26].
Behavioral tests
The hindlimb locomotor function recovery was evaluated using the Basso, Beattie, and Bresnahan (BBB) locomotor scale as previously described [
27], after MIF or CCL5 treatment on 0, 7, 14, and 21 days after surgery. Three well-trained investigators who were blind to the study observed the behavior of rats for 5 min. The BBB score ranged from 0 to 21 according to the rating scale. Every rat had a BBB score of 21 before surgery. The BBB score would become 0 to 1 after a successful SCI.
Statistical analysis
Statistical significance of differences between groups was analyzed by one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc comparisons tests with SPSS 15.0 (SPSS, Chicago, IL, USA). Normality and homoscedasticity of the data were verified before any statistical analysis using Levene’s test. Statistical significance was set at P < 0.05.
Discussion
Emerging evidence has shown that MIF plays a role as a neuroimmuno-modulator in the CNS. Multiple cell types in CNS express this protein, such as microglia, fibroblasts, pituitary cells, endothelial cells, neurons, and neural stem cell progenitors [
35]. Aberrant expression of MIF has shown to result in several pathological diseases of the CNS including Alzheimer’s disease, autism spectrum disorders, encephalomyelitis, and tumorigenesis [
35‐
38]. In the acute phase of spinal cord injury, MIF contributes to neuropathological impairments through promoting neuronal death and inflammatory activation [
14,
16]. It has been thought that microglia and other leukocytes are main resources of inflammatory cytokines in response to MIF stimuli [
13,
39]. However, inflammatory signal pathway in astrocytes can also be activated by MIF through phosphorylation of ERK [
18]. Here, we revealed a novel role of MIF in facilitating CCL5 production of astrocytes through activation of JNK, suggesting that MIF-induced releases of cytokines and chemokines are associated with multiple intracellular signals. Previous reports have shown that M1 and M2 macrophages populate the injury site with relatively equal distribution within the first week after SCI [
40,
41]. MIF-induced CCL5 release from astrocytes is primarily implicated in the cell events of M2 macrophages.
MIF regulates distinct intracellular signaling in a cell type-dependent way. This factor has been shown to interact with CD74 receptor on macrophages, astrocytes, fibroblasts, tumor cells, or B lymphocytes, resulting in sustained activation of ERK1/2 kinase that brings in various effects [
13,
18,
42]. Activation of MIF on JNK signaling has been identified in fibroblasts and T cell lines, in which phosphorylation of JNK is regulated by kinases PI3K and SRC [
43]. In the CD11b
+Gr-1
+ myeloid cells, MIF is capable of potentiating chemotaxis, differentiation, and pro-angiogenesis through activation of p38/MAPK and PI3K/AKT signal pathways [
44]. In the present study, we demonstrated that MIF/CD74 axis was able to regulate activities of ERK, P38, and JNK in astrocytes, suggesting a multifunctionality of MIF on astrocytes.
CCL5 induces the migration and recruitment of a wide variety of cells including T cells, dendritic cells, NK cells, eosinophils, basophils, mast cells, and endothelial progenitor cells [
9,
45]. Interestingly, its effects on chemotaxis of macrophages are found to have tissue specificity. For examples, CCL5 is involved in recruitment and survival of macrophages in human adipose tissue [
46] and in accumulation of macrophage in the kidney, liver, and peripheral nervous tissues [
47‐
49]. In the CNS, however, the role of CCL5 in recruitment of inflammatory cells is controversial. In the hippocampi of mice, CCL5 has been shown to be not critical for accumulation of microglia [
2]. We revealed that CCL5 primarily facilitates migration of IL-13-incubated macrophages, in consistency with that of IL-4-treated M2 macrophages [
10]. The discrepancy may be attributed to the distinct phenotypes of microglia, either a greater recruitment of monocyte-derived macrophages in SCI or the alternative activation status stimulated by specific milieu [
10,
50]. These results indicate that CCL5 alternatively facilitates accumulation of macrophages, depending on the cell subtype.
CCL5 is inducibly produced by invading pathogens or proinflammatory cytokines through activation of intracellular signals in a cell-specific manner [
9,
31]. HIV-1 induces CCL5 primarily by transcriptional activation, while bacterial lipopolysaccharide (LPS) induces CCL5 in microglia via activation of TLR4 receptor [
51]. Cytokine IL-1 is able to induce expression of CCL5 in astrocytes through phosphorylation of P38 or JNK, but not of ERK [
31]. In the present study, we displayed that MIF induced CCL5 production in astrocytes through activation of JNK signaling. These results indicate that the regulatory mechanism of CCL5 expression is differential in different cell types.